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The cytomegalovirus (CMV) enhancer is a highly complex regulatory region containing multiple elements
that interact with a variety of host-encoded transcription factors. Many of these sequence elements are con-
served among the different species strains of CMV, although the arrangement of the various elements and
overall sequence composition of the CMV enhancers differ remarkably. To delineate the importance of this
region to a productive infection and to explore the possibility of generating a murine CMV (MCMV) under the
control of human CMV (HCMV) genetic elements, the MCMV enhancer was resected and replaced either with
nonregulatory sequences or with paralogous sequences from HCMV. The effects of these various deletions and
substitutions on viral growth in transfected or infected tissue-culture cells were evaluated. We found that
mutations in MCMV that eliminate or substitute for the enhancer with nonregulatory sequences showed a
severe deficiency in virus synthesis. This growth defect is effectively complemented by the homologous MCMV
enhancer as well as the HCMV enhancer. In the latter case, the chimeric viruses (hybrid MCMV strains)
containing the molecularly shuffled human enhancer exhibit infectious kinetics similar to that of parental
wild-type and wild-type revertant MCMV. These results also show that open reading frames m124, m124.1, and
m125 located within the enhancer region are nonessential for growth of MCMV in cells. Most importantly, we
conclude that the enhancer of MCMV is required for optimal infection and that its diverged human counter-
part can advantageously replace its role in promoting viral infectivity.
Members of the species-specific cytomegalovirus (CMV)
family possess potent transcriptional enhancers upstream of
their major immediate-early promoters (MIEPs) (6, 10, 40,
41). The MIEP is one of the first promoters to activate upon
infection driving expression of key regulatory immediate-early
(IE) proteins of the virus. In addition, stringent regulation of
its activity in vivo implicates an important role for the MIEP in
viral cell-type tropism (4, 5, 22). Thus, transcriptional regula-
tion of the MIEP by the enhancer is believed to play a pivotal
role in determining the outcome of a productive infection (13).
The MIEP enhancers of the CMV family are highly complex
and contain multiple arrays of interdigitating repeat and
unique sequence elements (reviewed in reference 13). The
arrangement of these regulatory modules and overall sequence
composition of the enhancers differ considerably between the
different species strains (6, 10, 40). The majority of cellular
transcription factors known to interact with the enhancer ele-
ments are regulated through signal transduction pathways. In
many instances, the same signal-regulated transcription factors
have been shown to interact among the different CMV enhanc-
ers (e.g., references 2, 3, and 9 and references therein). It
therefore appears that while these enhancers differ in primary
sequence structure, their functional regulatory elements are
highly related. In this connection, it is noteworthy that many of
the different species members of the CMV family also share
many biological characteristics.
A limited number of mutations have been characterized in
regions closely associated with the MIEP enhancer in both
murine (MCMV) and human (HCMV) CMVs (7, 29, 30, 32,
34). In HCMV and MCMV, genetic disruption of the ie1 open
reading frames (ORFs) (whose transcripts are initiated from
their MIEPs) have shown that while the ie1 protein is nones-
sential for viral growth, it is necessary for optimal infection (15,
32, 34). Importantly, few mutations have been successfully
constructed in the MIEP locus, and so far none have been
generated in the enhancer region. In HCMV, a region imme-
diately upstream of the enhancer encompassing the modulator
region of the MIEP has been deleted and shown not to be
essential for MIEP activity in infected differentiated and un-
differentiated NT2 cells and human foreskin fibroblasts (30). It
therefore appears that mutations in regions closely associated
with MIEP enhancer are nonessential for determining a pro-
ductive infection. However, it is likely that the lack of charac-
terized mutants in the enhancer region occurs because of the
difficulty in generating virus mutants with growth disadvan-
tages. Recently, we (M.M. and U.K.) have reported a novel
strategy for the genetic manipulation of the MCMV genome,
based on the cloning of the infectious viral genome as a bac-
terial artificial chromosome (BAC) in Escherichia coli (32).
This approach provides a useful system for the study of virus
mutants with growth defects. To date, the predicted impor-
tance of the enhancer of CMV to infection remains untested.
In this study, we show by using the MCMV BAC system, that
the enhancer of MCMV plays an important role in promoting
a productive infection. We also show that wild-type growth
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characteristics can be completely restored to enhancerless vi-
rus, by linking in cis the homologous MCMV or heterologous
HCMV enhancer. Moreover, the genetic complementation
studies with the human enhancer provide direct evidence that
the enhancer is not involved in restricting the species-specific
host range of a CMV infection.
MATERIALS AND METHODS
Virus and cells. Murine NIH 3T3 fibroblasts (ATCC CRL1658) were propa-
gated in Dulbecco’s modified essential medium supplemented with 2 mM glu-
tamine, 100 U of penicillin per ml, 100 mg of gentamicin per ml, and 10% calf
serum. Mouse embryonic fibroblasts (MEFs), derived from the embryos of timed
pregnant BALB/c.ByJ mice on day 19 of gestation, were cultured in the same
medium as NIH 3T3 cells, except that 10% fetal bovine serum was used instead
of calf serum. The Smith strain of MCMV, originally obtained from Ann Camp-
bell (Eastern Virginia Medical School), was used as the parental wild-type
MCMV in this study. Stocks of MCMV were prepared in NIH 3T3 cells, and
titers were determined by standard plaque assay on NIH 3T3 cells.
Plasmid constructs. Recombinant plasmids were constructed according to
established procedures (28). Plasmid pBam25 containing the sequences from
176441 to 187035 of the MCMV genome placed into the BamHI site of pA-
CYC184 has been described previously (named pAMB25 in reference 18). The
construction of pBam25H was done as follows: primers dNN and BlpI were used
to amplify a 616-bp fragment from the HCMV enhancer with pMIEP(21114/
1112)CAT as a template (14). Primer dNN (59-gcc ctt taa atg cat aaa gcg gcc gct
gca tac gtt gta tcc ata tc-39) contains a NotI site, an NsiI site, and a DraI site
adjacent to nucleotide 2667 (relative to the ie1/ie2 HCMV transcription start
site) of the HCMV enhancer. Primer BlpI (59-gta cgc tca gcc cgc cca ttt gcg tca
atg ggg c-39) contains an EspI site adjacent to nucleotide 252 (relative to the
ie1/ie2 HCMV transcription start site) of the HCMV enhancer. The resulting
PCR fragment was digested with EspI and DraI and inserted into NdeI-EspI-
digested pON401 (with the NdeI site filled in [29]) to generate pON401H. A
2.7-kbp MluI fragment of pON401H was inserted into MluI-digested pBam25 to
create pBam25H.
Plasmid pIE111H was used for construction of enhancer deletions. pIE111H
was generated by cloning the EcoRI-HindIII fragment (nucleotides 177008 to
180728) from pIE111 (31) into pUC19 followed by insertion of the 6.6-kb
HindIII fragment of pON401H. To construct a plasmid that contains a deletion
from nucleotides 248 to 21191 of the MCMV enhancer, pIE111H was digested
by EspI and NotI, filled in with Klenow polymerase, and religated, resulting in
plasmid pdEnh17. The construction of plasmid pdEnhLuc was done as follows:
primer luc. (for 59-cat cta ggt ctc ctt aag taa tcg act cgc cta ggc cc-39 containing
an EspI site) and primer luc. rev (59-ggg cct agg tcg ccg gcg gtg gac tat agg aaa
cat-39 containing a NotI site) were used to amplify a 770-bp fragment from the
luciferase gene (corresponding to amino acids 196 to 450 of the luc [luciferase]
ORF). The resulting PCR fragment was digested with EspI and NotI and inserted
into the EspI-NotI-digested pIE111H.
Mutagenesis of the MCMV BAC plasmid by the two-step replacement strategy
requires about 2.5 to 3 kb of homologous sequences on each side of the mutation
(32, 37). To provide the required homologies, plasmid pUC-L (containing the
MCMV HindIII L fragment cloned into pUC19) was digested with HpaI and
NcoI, and an adapter molecule containing EcoRI and SalI sites (underlined) was
inserted (forward, 59-tag gga taa cag ggt aat gaa ttc att taa tac tag tgt cga cg-39;
reverse, 59-cat gcg tcg aca cta gta tta aat gaa ttc att acc ctg tta tcc cta-39), resulting
in plasmid pUC-LO. To provide the homology on the other side of the enhancer,
an SpeI site (MCMV nucleotide 178736) in plasmid pIE111 (31) was converted
to a MunI site by insertion of an oligonucleotide (59-cta ggg caa ttg cc-39). Next,
a 3.9-kb MunI fragment (nucleotides 178736 to 182682) was isolated and inserted
into the EcoRI site of the adapter in plasmid pUC-LO, leading to plasmid
pEnhDel. A 7.5-kb SalI fragment from pEnhDel was transferred to the shuttle
plasmid pMBO96 (37) and used to introduce the 1.6-kb MunI-HpaI deletion into
the MCMV BAC plasmid pSM3 and to generate BAC plasmid pE1. The MCMV
BAC plasmid pSM3 (32) contains the MCMV genome with BAC vector se-
quences replacing a nonessential region for replication in vitro (spanning nucle-
otides 209756 to 217934 within the HindIII E9 fragment) of the viral genome.
Therefore, ORFs m151 to m158 are completely or partially deleted in pSM3. To
construct the shuttle plasmid for introduction of the EspI-NdeI deletion of
the MCMV enhancer into BAC plasmid pSM3, the 1.0-kb MluI fragment of
pEnhDel was replaced with the 1.5-kb MluI fragment from plasmid pdEnh17,
and the 8-kb SalI fragment was transferred to pMBO96. To introduce the
luciferase stuffer mutation into the BAC plasmid pSM3, the 1.0-kb MluI frag-
ment of pEnhDel was replaced with the 2.2-kb MluI fragment from plasmid
pdEnhLuc, and the 8.7-kb SalI fragment was transferred to the shuttle plasmid
pST76-A (37a).
BAC mutagenesis. Mutagenesis of the MCMV BAC plasmid pSM3 was per-
formed as described previously (32). In brief, shuttle plasmids were electropo-
rated into E. coli CBTS bacteria (20) that already contained the BAC plasmid
pSM3. Note that E. coli CBTS is RecA1 at 30°C and virtually RecA2 at tem-
peratures higher than 37°C (the CBTS strain was constructed by M. O’Connor,
University of California Irvine). Transformants were selected at 30°C on Luria
broth (LB) plates containing chloramphenicol (12.5 mg/ml) and tetracycline (10
mg/ml) or chloramphenicol with ampicillin (50mg/ml), using shuttle plasmid
pMB097 or pST76-A, respectively. Clones that formed cointegrates were iden-
tified by streaking the bacteria on new LB plates followed by incubation at 43°C.
To allow resolution of the cointegrates, clones were streaked on LB plates
containing chloramphenicol only and incubated at 30°C. Bacteria were re-
streaked on LB plates with chloramphenicol to separate clones that contain
resolved plasmids and clones that still contain cointegrates. Clones with resolved
plasmids were identified by screening for the loss of the antibiotic marker of the
shuttle plasmid. Usually, about 5 to 10% of the clones resolved the cointegrates.
Finally, BAC plasmid DNA was isolated from 10-ml overnight cultures by the
alkaline lysis procedure (28) and characterized by restriction enzyme digestion to
identify BAC plasmids that received the mutation. Midi preparations of BAC
plasmids were prepared from 100-ml E. coli cultures as described previously (28,
32).
Transfections and virus construction. To generate recombinant viruses, BAC
plasmids were transfected, in the absence or presence of pBam25 or pBam25H,
into NIH 3T3 cells (in six-well dishes) by the calcium phosphate precipitation
technique essentially as described previously (28). Six hours posttransfection,
cells were treated with glycerol (15% glycerol in HEPES-buffered saline) for 3
min as described previously (28). The progeny virus that replicates in these
cultures was harvested when 100% cytopathic effect was observed in the cultures
and then was used to infect fresh cells. Two independent recombinants of the
hMCMV-ES (from two independent cotransfections of pE1 with pBam25H)
hybrid and one recombinant MCMVrev (from a cotransfection of pE1 with
pBam25) were subjected to three rounds of plaque purification before a high-
titer stock was prepared.
Viral infections. NIH 3T3 cells or MEFs were infected with wild-type MCMV
or different MCMV recombinants at the different multiplicities of infection
(MOIs) indicated in the figure legends. After a 1-h adsorption period, the virus
inoculum was removed, the cultures were washed three times with phosphate-
buffered saline, and fresh medium was added. At different times after infection,
the supernatants of three independent cultures were harvested, frozen, and
thawed, and infectious virus was quantitated by standard plaque assay on NIH
3T3 cells. For selective expression of IE transcripts, the cultures were incubated
from 30 min prior to infection and up to 12 h postinfection in the presence of
cycloheximide (100 mg/ml).
DNA and RNA analysis. Total cell DNA was isolated from infected NIH 3T3
cells (in 60-mm-diameter tissue culture dish) when 100% cytopathic effect was
observed in the cultures. Briefly, infected cells were scraped, washed twice with
phosphate-buffered saline, and lysed in 1 ml of a solution containing 10 mM Tris
(pH 7.8), 10 mM EDTA, 0.5% sodium dodecyl sulfate (SDS), and 250 mg of
proteinase K per ml, and incubated at 55°C for 4 h. DNA was then purified by
phenol-chloroform extraction and precipitated with ethanol. When DNA restric-
tion enzyme patterns were analyzed, viral DNA fragments after restriction en-
zyme digestion were run on 0.5% agarose gels for approximately 18 h at 0.5
V/cm. DNA blotting was conducted as described previously (28). The HCMV
enhancer-specific probe used was a 0.34-kbp SpeI-SnaBI fragment from pMIEP
(21145/1112)CAT. Whole-cell RNA was isolated from either uninfected or
infected NIH 3T3 cells (in six-well dishes) by using RNAzol B (Tel-Test, Inc.,
Friendswood, Tex.) according to the manufacturer’s protocol. Northern blot
analyses were performed as described in reference 28. Two to eight micrograms
of RNA was separated by electrophoresis on a 1% agarose gel containing 2.2 M
formaldehyde, transferred to a nylon membrane, and hybridized with a 1.6-kbp
MluI-HindIII fragment from pON401 to specifically detect ie1/ie3 transcripts
(29). The probes used were isolated from agarose gels and then radiolabeled with
[a-32P]dATP by the random-primed labeling method (12).
Immunoblot analyses. NIH 3T3 cells (in six-well dishes) were infected with
MCMV at an MOI of 0.5 PFU/cell. At different times after infection, samples
were lysed in protein sample buffer, vortexed, and boiled for 5 min. The polypep-
tides of cell lysates were separated by SDS-polyacrylamide gel electrophoresis
(PAGE) (8% polyacrylamide) and transferred to nitrocellulose filters. Filters
were incubated with an ie1-specific monoclonal antibody, Croma 101, and as a
secondary antibody horseradish peroxidase-conjugated goat anti-mouse immu-
noglobulin G (Amersham, Buckinghamshire, England) was used. Blots were de-
veloped with the Enhancer chemiluminescence system (Amersham) according to
the manufacturer’s protocol.
RESULTS
Generation of enhancerless MCMV genomes. To determine
if the enhancer is essential for efficient viral growth in tissue
culture cells, a series of recombinant MCMV genomes lacking
enhancer sequences were constructed by using the recently de-
scribed MCMV BAC system (32). In this system, the MCMV
genome has been cloned as a BAC in E. coli, and viral progeny
can be reconstituted by transfecting the MCMV BAC plasmid
into eukaryotic cells permissive for MCMV. As a parental
BAC plasmid for the generation of BACs carrying enhancer-
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less viral genomes, we used pSM3. The BAC plasmid pSM3
contains the MCMV genome with BAC vector sequences re-
placing a nonessential region for replication in vitro within the
HindIII E9 fragment at the right-terminal end of the viral
genome (spanning nucleotides 209756 to 217934). A schematic
representation of the various BAC recombinant genomes con-
structed is summarized in Fig. 1. In the first MCMV BAC
plasmid, pE1, an MunI-HpaI fragment of approximately 1.6
kbp in the HindIII L fragment of parental BAC pSM3 is
deleted. Deletion of this 1.6-kbp fragment, which encompasses
nucleotide sequences from 1209 to 21421 of the IE region,
effectively removes the complete MIEP regulatory region and
also disrupts the first exon of ie1/ie3. To generate a less exten-
sive disruption of the MIEP in which only enhancer sequences
have been removed, a 1.1-kbp EspI-NdeI sequence (within the
HindIII L fragment) extending from nucleotide positions 248
to 21191 of the MCMV MIEP was resected from pSM3 to
construct the enhancerless BAC plasmid pSM3dE (see Fig. 1
and Materials and Methods for details). In addition, and to
maintain the relative positions of the promoters flanking the
MCMV enhancer, a BAC plasmid, pSM3dE::luc, that contains
a stuffer fragment replacing the deleted enhancer segment was
generated (Fig. 1). In pSM3dE::luc, an internal nonregulatory
770-bp fragment from the firefly luciferase reporter gene was
inserted within nucleotides 248 and 21191 of the enhancer
region of MCMV. To verify the structure of the recombinant
BAC plasmids generated, their HindIII restriction patterns
were analyzed. As shown in Fig. 2, in comparison with the
parental BAC plasmid pSM3, the recombinant enhancerless
MCMV BAC plasmids lack the wild-type 7.1-kbp HindIII L
FIG. 1. Construction of enhancerless MCMV BAC genomes. The top line represents the HindIII map of the wild-type (Wt) MCMV genome, with the HindIII K
and L regions expanded below to show the region containing the MIE genes (ie1 to ie3). The MCMV BAC plasmids pE1, pSM3dE, and pSM3dE::luc, shown below
the wild-type MCMV genome, were generated by homologous recombination in E. coli with pSM3 as the parental MCMV BAC genome as indicated in Materials and
Methods. A MunI-HpaI fragment (from 1209 to 21421 relative to the ie1/ie3 MCMV transcription start site) in the HindIII L fragment of the wild-type MCMV
genome was removed to generate pE1. In pSM3dE, an EspI-NdeI fragment (from nucleotide sequences 248 to 21191 relative to the ie1/ie3 MCMV transcription start
site) was deleted in the HindIII L fragment of the wild-type MCMV genome. The MCMV BAC plasmid pSM3dE::luc contains a 770-bp fragment from the luciferase
gene replacing nucleotide sequences from 248 to 21191 (relative to the ie1/ie3 MCMV transcription start site) in the HindIII L fragment of the wild-type MCMV
genome. The illustration is not drawn to scale.
FIG. 2. Structural analysis of enhancerless MCMV BAC genomes. Ethidium
bromide-stained agarose gels of HindIII-digested BAC plasmids pSM3 (1), pE1
(2), pSM3dE (3), and pSM3dE::luc (4) after separation on a 0.5% agarose gel.
The HindIII fragment name (11) is indicated to the right of the set of lanes, and
the size markers are shown at the left margin. The size of the new HindIII L
fragments is indicated with an arrow at the right margin.
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fragment, which instead is replaced by the expected 5.5-kbp
fragment in pE1, 6.0-kbp fragment in pSM3dE, and 6.7-kbp
fragment in pSM3dE:luc. In addition, comparison of the XbaI
and EcoRI fragment profiles with those of parental BAC pSM3
indicated that pE1, pSM3dE, and pSM3dE::luc were free of
any detectable deletions or insertions in other regions outside
the HindIII L fragment of the viral genome (data not shown).
These results demonstrate the successful deletion of the en-
hancer and its replacement by a stuffer fragment in the recom-
binant BAC plasmids pE1, pSM3dE, and pSM3dE::luc, respec-
tively.
Requirement of the enhancer region for viral DNA infectiv-
ity. To test directly the significance of the enhancer to in-
fection, recombinant MCMV BAC genomes either contain-
ing (pSM3) or lacking the MIEP enhancer region (pE1 and
pSM3dE) were prepared from bacteria and transfected into
NIH 3T3 cells, and viral DNA infectivity was assessed by
plaque formation. Note that in pE1, the entire MIEP region
has been deleted, whereas in pSM3dE, the MIEP is truncated
at position 248 and therefore lacks exclusively enhancer se-
quences while retaining the wild-type MIEP core promoter
(TATA box) element. The results from this set of experiments
are shown in Table 1. As expected, numerous plaques devel-
oped in NIH 3T3 cells when transfected with the wild-type
MCMV BAC plasmid, pSM3, and cultures reached a complete
cytopathic effect within 9 days. In contrast, NIH 3T3 cells
transfected with the recombinant MCMV genome containing
the large 1.6-kbp deletion in the MIEP enhancer, pE1, failed to
develop any plaques. These results suggest that elimination of
the complete MIEP, including part of exon 1 of ie1/ie3, gen-
erates a replication-incompetent virus. When NIH 3T3 cells
were transfected with pSM3dE, a minimal number of small
plaques were produced, and cultures took more than twice as
long (24 days) to reach cytopathic effect (Table 1). Similar
results were achieved by transfecting the MCMV BAC plas-
mids into MEFs (data not shown). Altogether, the results of
these experiments are consistent with the enhancer being im-
portant for optimal infectivity.
In pSM3dE, the 1.1-kbp EspI-NdeI deletion of enhancer
sequences (from nucleotide positions 248 to 21191 of the
MCMV-MIEP) results in positioning the ie2 promoter-regu-
latory region immediately adjacent to the MIEP TATA box
(31) (Fig. 1). Specifically, in this BAC plasmid, nucleotide po-
sition 248 of the MCMV-MIEP enhancer is immediately ad-
jacent to nucleotide position 2183 relative to the ie2 transcrip-
tion start site. Thus, it is possible that the minimal infectivity
detected for pSM3dE in permissive cells is due to partial com-
pensation of MIEP activity by the MIEP TATA box alone or
by regulatory elements from the ie2 promoter. In order to
maintain an appropriate distance between the ie1 and ie2 pro-
moters, nonregulatory DNA was inserted in place of the enhanc-
er. Accordingly, the resulting recombinant, named pSM3dE::
luc, was next analyzed for DNA infectivity. As shown in Table
1, this recombinant when transfected in NIH 3T3 or MEF cells
developed a minimal number of small plaques. These results
therefore suggest that while there is an important requirement
of the enhancer region for a productive infection, it is not ab-
solutely essential.
Complementation of viral DNA infectivity of enhancerless
MCMV by transfection of cells with an ie1/ie3 expression plas-
mid. In the next set of experiments, we sought to determine
whether the defect in infectivity observed in the enhancer-de-
ficient genomes is due to genetic alteration of the IE locus alone.
For this purpose, we used a recombinant plasmid, pBam25,
that expresses ie1/ie3 genes upon transfection in NIH 3T3 cells
(Fig. 3 and data not shown). In the presence of pBam25,
approximately equal numbers of plaques were developed for
each enhancerless recombinant compared with reconstituted
MCMV derived from pSM3 (Table 1). These results demon-
strate that the failure of enhancerless recombinants to effi-
ciently form plaques is due to a specific alteration of the IE
locus.
To further establish that the only mutation introduced into
the enhancerless MCMV recombinant exists in the specific IE
region deleted, we sought to rescue pE1 by selecting for a re-
vertant wild-type virus in the presence of cotransfected pBam25
(Fig. 3). In these experiments, new cell monolayers were infect-
ed with supernatants derived from pE1 and pBam25 cotrans-
fected cells, and a revertant virus was subsequently purified by
multiple rounds of plaque purification. Lane 2 in Fig. 4 shows
that the DNA fragment profile following HindIII digestion for
the revertant MCMV genome exhibited, as expected, the nat-
ural HindIII fragment of 7.1 kbp in place of the 5.5-kbp
HindIII L fragment present in the enhancerless genome pE1
(compare lane 2 in Fig. 4 with lane 2 in Fig. 2). We next ex-
amined the growth kinetics of plaque-purified revertant virus
compared with those of the parental wild-type MCMV. The
revertant wild-type and parental wild-type viruses were found
to have similar growth kinetics (Fig. 5). These results demon-
strate that genetic ablation of the complete MIEP enhancer,
including part of exon 1 of ie1/ie3, results in the inability of the
virus to produce new progeny. In addition, these results sup-
port the conclusion that the enhancer of MCMV is important
for effecting a productive viral infection, but it is not absolutely
essential.
Genetic complementation and restoration of growth of en-
hancerless MCMV by the HCMV enhancer. Since the enhanc-
er region of MCMV contains a number of putative ORFs (m124,
m124.1, and m125) (38), it is possible that the loss of these
MCMV-specific sequences may be responsible, in part, for the
severely impaired ability of enhancerless MCMV to grow. In
order to test this hypothesis and to explore the possibility of
whether the human enhancer can rescue growth, we sought to
construct a hybrid virus that substituted the MCMV enhancer
for the HCMV enhancer. For these experiments, we first con-
structed a plasmid, pBam25H, containing the MCMV-MIE re-
gion in which sequences from 248 to 21191 of the MCMV
enhancer were replaced by the paralogous sequences from 252
to 2667 of the HCMV enhancer (Fig. 3 [see Materials and
Methods for details]). We next tested the ability of pBam25H
to complement in trans the growth defect of the enhancerless
BAC plasmid (pE1) in transient cotransfection assays. In these
experiments, cotransfection of pE1 and pBam25H in NIH 3T3
cells led to the development of plaques that took around 9 days
to reach a complete cytopathic effect. Therefore, these results
indicate that the severe deficiency of enhancerless MCMV to
grow is not due to the loss of expression from one of the
TABLE 1. Transfection of NIH 3T3 cells with pSM3 or
recombinant MCMV BAC plasmids in the
presence and absence of pBam25
Transfection
conditiona
No. of plaques (days to detection) in cultureb
pSM3 pE1 pSM3dE pSM3dE::luc
No pBam25 28 (5–9) 0 5 (8–24) 2 (7–26)
pBam25 25 (4–8) 30 (8–13) 50 (6–12) 32 (7–12)
a pBam25, a plasmid expressing ie1 and ie3, carries a BamHI fragment con-
taining sequences from 176441 to 187035 of the MCMV genome.
b Shown is the number of plaques first developed in the cultures. In paren-
theses is shown the number of days after transfection when plaques were initially
detected and when cultures reached a complete cytopathic effect.
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putative ORFs (m124-m125) that overlap the enhancer region
and further suggest that the HCMV enhancer may comple-
ment an enhancerless MCMV.
Accordingly, we next attempted to isolate a recombinant ge-
nome containing the enhancer swap. For these experiments, new
cell monolayers were infected with supernatants derived from
two independent cotransfections of pE1 and pBam25H. From
these transfer experiments, two independent hybrid strains,
hMCMV-ES1 and hMCMV-ES2, were generated after three
rounds of plaque purification.
In order to investigate the cis replacement of the MCMV
enhancer by its human counterpart and confirm the integrity of
the hybrid viruses, NIH 3T3 cells were infected with hMCMV-
ES1 and hMCMV-ES2, and total cell DNA was isolated when
cells showed a complete cytopathic effect. As expected, when
the genomes of the two chimeric viruses were analyzed by
HindIII digestion, the appropriate HindIII L fragment of 7.1
kbp present in wild-type MCMV was reduced to a 6.6-kb frag-
ment as a result of the replacement of the MCMV enhancer by
the HCMV enhancer (Fig. 4). Furthermore, these and other
restriction enzyme digestion analyses of hMCMV-ES1 and
hMCMV-ES2 in comparison with wild-type MCMV showed
identical banding patterns outside the HindIII L region (Fig. 4
and data not shown). In addition, hybridization with a radio-
labelled HCMV enhancer probe specifically detected the 6.6-
kbp fragment in the two chimeric viruses but not any fragments
in the wild-type MCMV and MCMVrev genomes (Fig. 4). To
further examine the integrity of the ES strains, the HCMV
enhancer region was sequenced. No changes were observed in
sequences from 252 to 2667 of the HCMV enhancer present
in the two chimeric strains after a minimum of six passages in
tissue culture (1). On the basis of the extensive restriction
enzyme digest analyses, sequencing, and hybridization studies,
we conclude that hMCMV ES-1 and hMCMV ES-2 contain
the HCMV enhancer in the place of its murine paralog.
To determine whether the enhancer exchange altered the
ability of the chimeric viruses to grow in cell culture, growth
analyses were performed at different MOIs. For these experi-
ments, NIH 3T3 cells were infected with hMCMV-ES1 and
hMCMV-ES2 at MOIs of 0.01 and 5, and viral titers in the
supernatant of the cultures were determined at different times
after infection and compared with that of the wild-type or
revertant MCMV. Figure 5 shows that both hMCMV-ES1 and
-2 strains exhibit growth properties remarkably similar to those
of wild-type and revertant MCMV strains as determined by
single-step (Fig. 5A) and multistep (Fig. 5B) growth analyses.
We next investigated to what extent expression of ie1/ie3
transcripts had been altered by the replacement of the MCMV
enhancer with the human counterpart. In wild-type MCMV-
FIG. 3. Construction of hMCMV-ES mutants. The top line represents the HindIII map of wild-type MCMV genome, with the HindIII K and L regions expanded
below to show the region containing the MIE genes (ie1 to ie3). In the MCMV BAC plasmid pE1, a MunI-HpaI fragment (from nucleotide sequences 1209 to 21421
relative to the ie1/ie3 MCMV transcription start site) has been deleted in the HindIII L region of the wild-type MCMV genome. Recombinant viruses MCMVrev and
hMCMV-ES were constructed by cotransfection of MCMV BAC plasmid pE1 with pBam25 or pBam25H, respectively, into NIH 3T3 cells. pBam25, a plasmid
expressing ie1 and ie3, carries a BamHI fragment containing sequences from 176441 to 187035 of the MCMV genome. pBam25H carries the BamHI fragment
(containing sequences from 176441 to 187035 of the MCMV genome) in which sequences from 248 to 21191 (relative to the ie1/ie3 MCMV transcription start site)
have been replaced by sequences from 252 to 2667 of the HCMV enhancer. The solid and hatched boxes represent the MCMV and HCMV enhancers, respectively.
The diagram is not drawn to scale.
FIG. 4. Structural analysis of hMCMV mutants. DNA isolated from NIH
3T3 cells infected with wild-type MCMV (1), MCMVrev (2), hMCMV-ES1 (3),
or hMCMV-ES2 (4) was subjected to HindIII digestion and separated on a 0.5%
agarose gel. Bands were visualized with ethidium bromide (A) or transferred to
nylon filters and hybridized to a 32P-labeled 340-bp SpeI-SnaBI fragment from
the HCMV enhancer (B). The HindIII fragment name (11) is indicated to the
left set of lines, and the sizes of the natural and new HindIII L fragments for each
virus are shown with an arrow.
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infected cells, ie1/ie3 expression is abundant at immediate-
early and late times, but is reduced during early times of
infection (39). Accordingly, NIH 3T3 cells were infected at an
MOI of 0.5 with hMCMV-ES1 and hMCMV-ES2, and RNA
was extracted at different times after infection and analyzed by
Northern blotting with an ie1/ie3-specific probe. To control for
RNA loading, Northern blots were also probed with a radio-
labelled cDNA probe to GAPDH (Fig. 6). Figure 6 shows that
the patterns observed for the major 2.75-kb ie1/ie3 transcripts
were quantitatively similar in cells infected by both strains of
hMCMV and wild-type MCMV or MCMVrev-infected cells.
These results indicate that the temporal expression pattern and
appropriate levels of ie1/ie3 RNA are synthesized upon infec-
tion with the enhancer swap strains. We next determined the
expression levels of ie1 protein in cells infected by these chi-
meric viruses. In MCMV-infected cells, the 89-kDa ie1 protein
can be initially detected at 1 h postinfection and is detectable
during the whole replication cycle (19, 31). NIH 3T3 cells were
infected with both isolates of hMCMV-ES, and wild-type or
revertant MCMV and cell lysates were prepared at different
times postinfection. Protein expression levels were monitored
by Western blotting with the ie1-specific antibody. As shown
in Fig. 7, at an MOI of 0.5 PFU/cell, temporal expression
patterns and levels of ie1 expression in cells infected with
the two hMCMV-ES isolates were comparable to those in
the revertant virus and wild-type MCMV-infected cells. Al-
together, these results demonstrate that the human en-
hancer can efficiently substitute for the MCMV enhancer in
tissue culture.
DISCUSSION
This study shows that the enhancer region of MCMV plays
a critical role for efficiently effecting productive infection in
tissue culture cells. We further demonstrate that genetically ex-
changing the MCMV enhancer with that from HCMV effec-
tively produces wild-type growth characteristics. These results
have a number of important implications for understanding
and exploiting the role of the enhancer in the CMV infectious
program.
Enhancer is important for MCMV growth. The results of
this study clearly show that enhancer-deficient strains or re-
combinant genomes of MCMV are severely compromised in
their ability to synthesize virus in infected or transfected cells.
Previous studies have indicated that enhancers play a number
of distinct roles in a viral life cycle. The most important role
served by a viral enhancer is in the initiation of the infectious
program by which it acts as a potent transcriptional activator
region for the viral IE genes. In agreement, our experiments
showing that a related but distinct enhancer can efficiently
substitute for the naturally occurring enhancer strongly suggest
that a primary function of this region is to increase the effi-
ciency of IE gene expression by serving as a potent activator of
transcription. These enhancer swap experiments might also
underscore the functional importance of the conserved reg-
ulatory elements within the HCMV and MCMV enhancers,
although we predict that any enhancer could substitute, in part,
for the CMV enhancer. Viral enhancers have also been impli-
cated in the maintenance of an open chromatin structure prior
FIG. 5. Growth kinetics of hMCMV-ES mutants. Murine NIH 3T3 cells were
infected at an MOI of 5 (A) or 0.01 PFU (B) per cell with wild-type (Wt) MCMV
(Smith strain), MCMVrev, hMCMV-ES1, or hMCMV-ES2. At the indicated
time points (hours) after infection (hpi) supernatants from the infected cultures
were harvested, and titers were determined by plaque assay on NIH 3T3 cells.
Each data point represents the average and standard deviation from three sep-
arate cultures.
FIG. 6. Expression of RNA kinetics of ie1/ie3 transcripts by hMCMV-ES
mutants. NIH 3T3 cells were mock infected (lane 1) or infected at an MOI of 0.5
PFU/cell with wild-type MCMV (lanes 2, 6, 10, and 14), hMCMV-ES1 (lanes 3,
7, 11, and 15), hMCMV-ES2 (lanes 4, 8, 12, and 16), and MCMVrev (lanes 5, 9,
13, and 17). Whole-cell RNA was harvested at the indicated times after infection
in the presence (lanes 2 to 5) or absence (lanes 1 and 6 to 17) of CH, separated
on a formaldehyde-agarose gel, transferred to a nylon membrane, and probed
with a 1.6-kb MluI-HindIII fragment from pON401 that was specific for ie1
transcripts. The position of the 2.75-kb transcripts is indicated on the right by an
arrow. The positions of the 18S and 28S rRNAs are shown. The blot was then
hybridized with a 32P-labeled GAPDH probe as an internal RNA control. The
1.4-kb GAPDH band detectable in all lanes is shown on the bottom panels.
FIG. 7. Expression kinetics of ie1 protein in hMCMV-ES-infected cells. NIH
3T3 cells were mock infected (lane 1) or infected at an MOI of 0.5 PFU/cell with
wild-type MCMV (lanes 2, 6, 10, and 14), hMCMV-ES1 (lanes 3, 7, 11, and 15),
hMCMV-ES2 (lanes 4, 8, 12, and 16), and MCMVrev (lanes 4, 9, 13, and 17). At
the indicated times after adsorption, samples were lysed, subjected to SDS-
PAGE analysis on 8% polyacrylamide gels, and reacted with an ie1 monoclonal
antibody. Molecular mass standards (M) appear on the left. The position of the
89-kDa protein is indicated by an arrowhead.
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to and after the initiation of replication (8). In this connection,
we note that in an infection of permissive cells by HCMV,
marked DNase I hypersensitivity is observed in the enhancer
region, indicating an open chromatin structure at early times of
infection (35). In addition, viral enhancers may directly poten-
tiate viral DNA replication (16, 17, 36) or may even be in-
volved in localizing virion DNA to preferred nuclear compart-
ments. It is conceivable that all of these possibilities may be
responsible for the requirement of the enhancer for optimal
MCMV infection. Whether the enhancer plays any direct role
in promoting MCMV DNA replication or modifying chroma-
tin structure remains to be determined.
Enhancer is not involved in the species restriction of CMV
in tissue-culture cells. The CMV family is highly species spe-
cific. In this regard, the role of an enhancer in initiating the
transcriptional program of a virus can, in principle, limit the
virus to productively infect a specific host or cell type (23, 25,
27, 33). Previous in vitro and in vivo studies have indicated that
the HCMV enhancer functions appropriately in mouse cells (4,
5, 22, 24), indicating that the strict species specificity of CMV
is not at the level of the MIEP. In agreement with this notion,
we provide in this study direct evidence that the enhancer is
not responsible for the species-specific restriction in the ability
of CMV to productively infect cells. At present, we cannot rule
out the possibility that the species-specific enhancers may re-
strict in vivo growth of CMV, although the transgenic studies
with the human enhancer indicate that this is unlikely to be the
case (4, 5, 22). Indeed, our preliminary experiments indicate
that hMCMV strains are capable of productively infecting the
mouse (1).
The new hMCMV strains and future implications. In this
study, we show that the HCMV enhancer can completely re-
store the growth deficiency of an enhancerless MCMV. Im-
portantly, these chimeric (hMCMV-ES) strains represent an
MCMV that is under the control of HCMV genetic elements
and thus may provide the development of a new model for
exploring the in vivo importance of select HCMV enhancer
elements during acute, latent, and reactivated infections. In
particular, mutations introduced in specific binding sites for
transcription factors used by the HCMV enhancer will clarify
the involvement of the various signal-regulated transcription
factors in controlling aspects of viral pathogenesis and latency.
Finally, the observation that viral growth can be inhibited by
eliminating the enhancer might have important implications
in the development of novel ligand-specific drugs for therapy
against CMV. For instance, it is possible to generate molecules
to recognize specific base pairs in the minor groove by using
hairpin polyamides (42) and the major groove by using DNA-
binding antibodies (26) or zinc finger chimeras (21).
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